Abbott Laboratories (NYSE:ABT) Releases Earnings Results, Hits Estimates

Abbott Laboratories (NYSE:ABT - Get Free Report) released its quarterly earnings results on Thursday. The healthcare product maker reported $1.26 earnings per share for the quarter, hitting analysts' consensus estimates of $1.26, Zacks reports. Abbott Laboratories had a return on equity of 19.01% and a net margin of 31.89%. The firm had revenue of $11.14 billion during the quarter, compared to analysts' expectations of $11.01 billion. During the same quarter in the prior year, the business earned $1.14 EPS. Abbott Laboratories's quarterly revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories updated its FY 2025 guidance to 5.100-5.200 EPS and its Q3 2025 guidance to 1.280-1.320 EPS.

Abbott Laboratories Stock Performance

Shares of NYSE:ABT traded up $3.30 on Friday, hitting $123.81. The company's stock had a trading volume of 19,570,335 shares, compared to its average volume of 6,275,093. Abbott Laboratories has a 12 month low of $99.71 and a 12 month high of $141.23. The company has a market capitalization of $215.41 billion, a price-to-earnings ratio of 16.06, a price-to-earnings-growth ratio of 2.50 and a beta of 0.73. The stock's 50-day moving average is $133.17 and its two-hundred day moving average is $129.38. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.27 and a current ratio of 1.78.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th will be paid a $0.59 dividend. The ex-dividend date of this dividend is Tuesday, July 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.91%. Abbott Laboratories's payout ratio is 30.61%.

Insider Activity

In related news, Director Sally E. Blount sold 2,600 shares of the firm's stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total transaction of $337,116.00. Following the completion of the transaction, the director owned 34,058 shares of the company's stock, valued at $4,415,960.28. This trade represents a 7.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.46% of the company's stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Abbott Laboratories stock. Brighton Jones LLC lifted its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 10.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 51,719 shares of the healthcare product maker's stock after purchasing an additional 4,755 shares during the quarter. Brighton Jones LLC's holdings in Abbott Laboratories were worth $5,850,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 75.18% of the company's stock.

Wall Street Analyst Weigh In

ABT has been the topic of a number of recent analyst reports. Leerink Partners initiated coverage on Abbott Laboratories in a research report on Monday, June 16th. They issued a "market perform" rating and a $143.00 target price on the stock. Wells Fargo & Company cut their target price on Abbott Laboratories from $147.00 to $142.00 and set an "overweight" rating on the stock in a research report on Friday. Mizuho raised their price objective on Abbott Laboratories from $130.00 to $140.00 and gave the stock a "neutral" rating in a research note on Wednesday. BTIG Research decreased their price objective on shares of Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating for the company in a report on Friday. Finally, Morgan Stanley increased their target price on shares of Abbott Laboratories from $127.00 to $137.00 and gave the stock an "equal weight" rating in a report on Tuesday. Five analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $144.47.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.